U.S. Markets closed

Baxter International Inc. (BAX)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
80.82-0.33 (-0.41%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close81.15
Open80.61
Bid80.06 x 1100
Ask81.90 x 900
Day's Range80.28 - 81.45
52 Week Range74.79 - 91.45
Volume4,311,338
Avg. Volume2,586,385
Market Cap40.64B
Beta (5Y Monthly)0.68
PE Ratio (TTM)39.04
EPS (TTM)2.07
Earnings DateJul 28, 2021 - Aug 02, 2021
Forward Dividend & Yield1.12 (1.28%)
Ex-Dividend DateJun 03, 2021
1y Target Est94.00
  • Business Wire

    Baxter to Host Second-Quarter 2021 Financial Results Conference Call for Investors

    DEERFIELD, Ill., Jun 15, 2021--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its second-quarter 2021 financial results on Thursday, July 29, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/8371319 to pre-register for the call and receive the call information.

  • Baxter's (BAX) Theranova-Enabled HDx Therapy Data Positive
    Zacks

    Baxter's (BAX) Theranova-Enabled HDx Therapy Data Positive

    Baxter's (BAX) Theranova-enabled HDx therapy is likely to boost clinical outcomes and lower healthcare resource utilization.

  • Baxter Presents Data at 58th ERA-EDTA Congress Indicating Theranova May Reduce Cardiovascular Events and Hospitalizations
    Business Wire

    Baxter Presents Data at 58th ERA-EDTA Congress Indicating Theranova May Reduce Cardiovascular Events and Hospitalizations

    Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced today new data showing expanded hemodialysis (HDx) therapy enabled by the Theranova dialyzer may reduce cardiovascular events by 35% and hospitalization rates by 18% according to a new, large, multicenter, retrospective study of Colombian dialysis patients treated with long-term HDx compared to propensity-matched patients treated with High-Flux Hemodialysis.1 The study "Effectiveness of medium cut-off versus high f